API | serelaxin

serelaxin Report issue

Biologics Recombinant protein Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Serelaxin is a medication which is marketed in Russia for the treatment of acute heart failure (AHF), targeting the relaxin receptor. It was also under development in other places in the world, including in the United States, Europe, and Asia, but ultimately was not marketed in these areas. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
serelaxin

More Chemistry

Pharmacology

Mechanisms of Action:
- Relaxin receptor 1 (Homo sapiens) ^UniProt
- Relaxin receptor 2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

human relaxin 2 (relaxin h2) | human relaxin recombinant | recombinant human relaxin | rlx030 | serelaxin

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Coronary Artery Disease (Phase 2)

Heart Failure (Phase 3)

Hypertension, Portal (Phase 2)

Kidney Failure, Chronic (Phase 1)

Labor, Induced (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 1)

Pre-Eclampsia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 16
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue